Oral metronomic cyclophosphamide in elderly with metastatic melanoma

Investigational New Drugs

Volumn 28, Issue 5, 2010, Pages 684-689

  Borne, Estelle ^a   Desmedt, Eve ^a   Duhamel, Alain ^a   Mirabel, Xavier ^b   Dziwniel, Véronique ^c   Maire, Cyril ^a   Florin, Valérie ^a   Martinot, Véronique ^d   Penel, Nicolas ^b   Vercambre Darras, Sophie ^a   Mortier, Laurent ^a,d  

^a UNIV LILLE   (France)

^b CENTRE OSCAR LAMBRET   (France)

^c ECOLE CENTRALE DE LILLE   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Cyclophosphamide; Frail elderly; Metastatic melanoma; Metronomic schedule

Indexed keywords

CYCLOPHOSPHAMIDE; ALKYLATING AGENT; ANGIOGENESIS INHIBITOR;

AGED; ANEMIA; ANOREXIA; ARTICLE; CHOLESTASIS; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FRAIL ELDERLY; GASTROINTESTINAL SYMPTOM; HOME CARE; HUMAN; INFECTION; INOPERABLE CANCER; KIDNEY FAILURE; LYMPHOCYTOPENIA; MALE; MELANOMA; METASTASIS; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; THROMBOCYTOPENIA; VERTIGO; WEIGHT REDUCTION; DRUG EFFECTS; IMMUNOLOGY; IMMUNOMODULATION; ORAL DRUG ADMINISTRATION; PATHOLOGY; SURVIVAL; VERY ELDERLY;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS, ALKYLATING; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; IMMUNOMODULATION; MALE; MELANOMA; NEOPLASM METASTASIS; SURVIVAL ANALYSIS;

EID: 77956060635     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-009-9298-5     Document Type: Article

References (43)

1. L Chérié-Challine J-M Halna L Remontet 2004 Situation épidémiologique du mélanome cutané en France et impact en termes de prévention Bull Epidémiol Hebd 2 5 8
2. D Nashan M Müller S Grabbe S Wustlich A Enk 2007 Systemic therapy of disseminated malignant melanoma: an evidence-based overview of the state-of-the-art in daily routine J Eur Acad Dermatol Venereol 21 1305 1318 10.1111/j.1468-3083.2007.02475.x 1:STN:280:DC%2BD2snjsFSgsA%3D%3D 17958834
3. A Sasse E Sasse L Clark L Ulloa O Clark 2008 Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma (review) Cochrane Database Syst Rev 24 CD005413
4. C Balch D Murray C Presant A Bartolucci 1984 Ineffectiveness of adjuvant chemotherapy using DTIC and cyclophosphamide in patients with resectable metastatic melanoma Surgery 95 454 459 1:STN:280:DyaL2c7nt1Kqsg%3D%3D 6369594
5. M Colleoni A Rocca MT Sandri L Zorzino G Masci F Nolè G Peruzzotti C Robertson L Orlando S Cinieri F de Braud G Viale A Goldhirsch 2002 Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels Ann Oncol 13 73 80 10.1093/annonc/mdf013 1:STN:280:DC%2BD387islyksw%3D%3D 11863115
6. G Bocci M Tuccori U Emmenegger V Liguori A Falcone RS Kerbel M Del Tacca 2005 Cyclophosphamide-methotrexate 'metronomic' chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation Ann Oncol 16 1243 1252 10.1093/annonc/mdi240 1:STN:280:DC%2BD2MzotFaltg%3D%3D 15905308
7. R Lord S Nair A Schache J Spicer N Somailhah V Khoo H Pandha 2007 Low dose metronomic oral cyclophosphamide for hormone resistant prostatic cancer: a phase II study J Urol 177 2136 2140 10.1016/j.juro.2007.01.143 1:CAS:528:DC%2BD2sXmslKlu78%3D 17509300
8. U Emmenegger S Man Y Shaked G Francia JW Wong DJ Hicklin RS Kerbel 2004 A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens Cancer Res 64 3994 4000 10.1158/0008-5472.CAN-04-0580 1:CAS:528:DC%2BD2cXksVKns7c%3D 15173013
9. CM Balch AC Buzaid SJ Soong MB Atkins N Cascinelli DG Coit ID Fleming JE Gershenwald A Houghton J Kirkwood K McMasters MF Mihm D Morton DS Reintgen MI Ross A Sober JA Thompson JF Thompson 2001 Final version of the American joint committee on cancer staging system for cutaneous melanoma J Clin Oncol 19 3635 3648 1:STN:280:DC%2BD3MvlvV2ktQ%3D%3D 11504745
10. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij MV Glabbeke O ATv MC Christian SG Gwyther 2000 New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 205 216 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D 10655437
11. J Homsi M Kashani-Sabet JL Messina A Daud 2005 Cutaneous melanoma: prognostic factors Cancer Control 12 223 229 16258493
12. N Bossard M Velten L Remontet A Belot N Maarouf A Bouvier A Guizard B Tretarre G Launoy M Colonna A Danzon F Molinie X Troussard N Bourdon-Raverdy P Carli A Jaffré C Bessaguet E Sauleau C Schvartz P Arveux M Maynadié P Grosclaude J Estève J Faivre 2007 Survival of cancer patients in France: a population-based study from the association of the french cancer registries (FRANCIM) Eur J Cancer 43 149 160 10.1016/j.ejca.2006.07.021 1:STN:280:DC%2BD2s%2FisFSmtQ%3D%3D 17084622
13. L Balducci 2007 Aging, frailty and chemotherapy Cancer Control 14 7 12 17242666
14. M Extermann 2007 Interaction between comorbidity and cancer Cancer Control 14 13 22 17242667
15. Carriere I, Dupuy A, Lacroux A, Cristol J, Delcourt C, Pathologies Liées à l'Age Study Group 2008 Biomarkers of inflammation and malnutrition associated with early death in healthy elderly people J Am Geriatr Soc 56 840 846 10.1111/j.1532-5415.2008.01677.x
16. W Satariano D Ragland 1994 The effect of comorbidity on 3-year survival of women with primary breast cancer Ann Intern Med 120 104 110 1:STN:280:DyaK2c%2FnvFWksQ%3D%3D 8256968
17. G Freyer J Geay S Touzet J Provencal B Weber J Jacquin G Ganem N Tubiana-Mathieu O Gisserot E Pujade-Lauraine 2005 Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study Ann Oncol 16 1795 1800 10.1093/annonc/mdi368 1:STN:280:DC%2BD2MrlvFGmug%3D%3D 16093275
18. A Kumar HP Soares L Balducci B Djulbegovic 2007 Treatment tolerance and efficacy in geriatric oncology : a systematic review of phase III randomized trials conducted by five National Cancer Institute-sponsored cooperative groups J Clin Oncol 25 1272 1276 10.1200/JCO.2006.09.2759 1:CAS:528: DC%2BD2sXkvFyms7o%3D 17401017
19. L Hutchins J Unger J Crowley 1999 Underrepresentation of patients 65 years of age and older in cancer treatment trials N Engl J Med 341 2061 2067 10.1056/NEJM199912303412706 1:STN:280:DC%2BD3c%2Fmt1Sjsg%3D%3D 10615079
20. H Gogas J Kirkwood V Sondak 2007 Chemotherapy for metastatic melanoma: time for a change? Cancer 109 455 464 10.1002/cncr.22427 1:CAS:528: DC%2BD2sXitV2itrw%3D 17200963
21. R Cashin P Lui M Machado M Hemels P Corey-Lisle T Einarson 2008 Advanced cutaneous malignant melanoma: a systematic review of economic and quality-of-life-studies Value Health 11 259 271 10.1111/j.1524-4733.2007.00243.x 18380638
22. M-F Avril S Aamdal JJ Grob A Hauschild P Mohr JJ Bonerandi M Weichenthal K Neuber T Bieber K Gilde VG Porta J Fra J Bonneterre P Saïag D Kamanabrou H Pehamberger J Sufliarsky JLG Larriba A Scherrer Y Menu 2004 Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study J Clin Oncol 22 1118 1125 10.1200/JCO.2004.04.165 1:CAS:528:DC%2BD2cXptlCku7Y%3D 15020614
23. D Hanahan R Weinberg 2000 The hallmarks of cancer Cell 100 57 70 10.1016/S0092-8674(00)81683-9 1:CAS:528:DC%2BD3cXks1CktA%3D%3D 10647931
24. M Awwad RJ North 1988 Cyclophosphamide (Cy)-facilitated adoptive immunotherapy of a Cy-resistant tumour. Evidence that Cy permits the expression of adoptive T-cell mediated immunity by removing suppressor T cells rather than by reducing tumour burden. Immunology 65 87 92 1:CAS:528:DyaL1cXlvVeitL4%3D 2972604
25. T Browder CE Butterfield BM Kräling B Shi B Marshall MS O'Reilly J Folkman 2000 Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer Cancer Res 60 1878 1886 1:CAS:528: DC%2BD3cXisVynurk%3D 10766175
26. G Mahabeleshwar T Byzoya 2007 Angiogenesis in melanoma Semin Oncol 34 555 565 10.1053/j.seminoncol.2007.09.009 1:CAS:528:DC%2BD1cXht1aqtr0%3D 18083379
27. SM Hellwig CA Damen NP Adrichem GH Blijham G Groenewegen AW Griffioen 1997 Endothelial CD34 is suppressed in human malignancies: role of angiogenic factors Cancer Lett 120 203 211 10.1016/S0304-3835(97)00310-8 1:CAS:528:DyaK2sXnt1eksL8%3D 9461038
28. AEM Dirkx E MGAo K Castermans S DWJvd VLJL Thijssen RPM Dings L Kwee KH Mayo J Wagstaff JCA Bouma-ter Steege AW Griffioen 2006 Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors FASEB J 20 621 630 10.1096/fj.05-4493com 1:CAS:528:DC%2BD28Xjtlaqs70%3D 16581970
29. AW Griffioen CA Damen S Martinotti GH Blijham G Groenewegen 1996 Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancy: role of angiogenic factors Cancer Res 56 1111 1117 1:CAS:528:DyaK28XhtlKktrs%3D 8640769
30. A Conforti D Ollila M Kelley G Gammon D Morton 1997 Update on active specific immunotherapy with melanoma vaccines J Surg Oncol 66 55 64 10.1002/(SICI)1096-9098(199709)66:1<55::AID-JSO12>3.0.CO;2-N 1:CAS:528:DyaK2sXmtl2mtL4%3D 9290695
31. M Salem A Kadima S El-Naggar M Rubinstein Y Chen W Gillanders D Cole 1997 Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells J Immunother 30 40 53 10.1097/01.cji.0000211311.28739.e3
32. AM Ercolini BH Ladle EA Manning LW Pfannenstiel TD Armstrong J-PH Machiels J Bieler L Emens R Reilly EM Jaffee 2005 Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response J Exp Med 201 1591 1602 10.1084/jem.20042167 1:CAS:528:DC%2BD2MXktlygu7c%3D 15883172
33. L Bracci F Moschella P Sestili V La Sorsa M Valentini I Canini S Baccarini S Maccari C Ramoni F Belardelli E Proietti 2007 Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration Clin Cancer Res 13 644 653 10.1158/1078-0432.CCR-06-1209 1:CAS:528:DC%2BD2sXoslSrsQ%3D%3D 17255288
34. A Tarhini S Agarwala 2006 Cutaneous melanoma: available therapy for metastatic disease Dermatol Ther 19 19 25 10.1111/j.1529-8019.2005.00052.x 16405566
35. L Balducci 2006 Management of cancer in the elderly Oncology (Williston Park) 20 135 143
36. F Bertolini S Paul P Mancuso S Monestiroli A Gobbi Y Shaked RS Kerbel 2003 Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells Cancer Res 63 4342 4346 1:CAS:528:DC%2BD3sXmtFekurY%3D 12907602
37. K Griffith E Read J Carrasquillo C Carter J Yang B Fischer P Aebersold B Packard M Yu S Rosenberg 1989 In vivo distribution of adoptively transferred indium-111-labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma J Natl Cancer Inst 81 1709 1717 10.1093/jnci/81.22.1709 1:STN:280:DyaK3c%2FktVOltQ%3D%3D 2810387
38. P Matar VR Rozados SI Gervasoni GO Scharovsky 2002 Th2/Th1 switch induced by a single low dose of cyclophosphamide in a rat metastatic lymphoma model Cancer Immunol Immunother 50 588 596 10.1007/s00262-001-0237-3 1:CAS:528:DC%2BD38XhsVens7w%3D 11807622
39. T Tatsumi L Kierstead E Ranieri L Gesualdo F Schena J Finke R Bukowski J Mueller-Berghaus J Kirkwood W Kwok W Storkus 2002 Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma J Exp Med 196 619 628 10.1084/jem.20012142 1:CAS:528:DC%2BD38XmvFKqtLg%3D 12208877
40. C Lutsiak RT Semnani RD Pascalis SVS Kashmiri J Scholm H Sabzevari 2005 Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide Blood 105 2862 2868 10.1182/blood-2004- 06-2410 1:CAS:528:DC%2BD2MXivFGmtLw%3D 15591121
41. S Ben-Efraim 2001 Immunomodulating anticancer alkylating drugs: targets and mechanisms of activity Curr Drug Targets 2 197 212 10.2174/1389450013348597 1:CAS:528:DC%2BD3MXktlSqsbs%3D 11469719
42. F Ghiringhelli C Menard PE Puig S Ladoire S Roux F Martin E Solary AL Cesne L Zitvogel B Chauffert 2007 Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T and NK effector functions in end stage cancer patients Cancer Immunol Immunother 56 641 648 10.1007/s00262-006- 0225-8 1:CAS:528:DC%2BD2sXisVaqtbY%3D 16960692
43. M Awwad RJ North 1989 Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: a consequence of eliminating precursor L3T4+ suppressor T-cells Cancer Res 49 1649 1654 1:CAS:528:DyaL1MXhvVGnurk%3D 2522344